Acarbose

Catalog No.S1271 Synonyms: BAY g 5421

For research use only.

Acarbose(BAY g 5421) is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.

Acarbose Chemical Structure

CAS No. 56180-94-0

Selleck's Acarbose has been cited by 1 Publication

Purity & Quality Control

Choose Selective Carbohydrate Metabolism Inhibitors

Biological Activity

Description Acarbose(BAY g 5421) is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.
Targets
alpha-glucosidase [1]
In vitro

Acarbose reversibly inhibits intestinal alpha-glucosidases, enzymes responsible for the metabolism of complex carbohydrates into absorbable monosaccharide units.[1]

In vivo Acarbose reduces the absorption of monosaccharides derived from dietary carbohydrates, which play an important role in the metabolism and toxicity of some chemical compounds. Acarbose alone potentiates carbon tetrachloride (CCl4) andacetaminophen (AP) hepatotoxicity, as evidenced by significantly increased levels of both alanine transaminase (ALT) and aspartate transaminase (AST) in the plasma of rats pretreated with acarbose. [2] Acarbose treatment suppresses weight gain and the development of hepatic steatosis in sqstm1 gene knockout mice. Acarbose treatment up-regulates hepatic expression of the pparalpha, ucp-2, and abca1 genes, as well as srebp1c, pparalpha, and ppargamma in adipose tissue. [3] Acarbose-treated rats have lower body weights at 3 months of age with unaltered food consumption, and a similar effect is seen with a high-fructose diet in the JCR:LA-corpulent rat. [4] Acarbose markedly improves postprandial hyperglycemia, postprandial insulin level, total cholesterol, triglyceride, and free fatty acid level in Goto-Kakizaki (GK) rats. Acarbose efficiently reduces the number of monocytes adherent to aortic endothelial layer, improves acetylcholine-dependent vasodilatation, and reduces intimal thickening of the aorta in GK rats. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 645.6
Formula

C25H43NO18

CAS No. 56180-94-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04665570 Recruiting Drug: BAY81-9783 (Acarbose/Metformin) Type 2 Diabetes Mellitus Bayer December 21 2020 --
NCT04180813 Terminated Drug: Linagliptin|Drug: Acarbose Diabetes Mellitus Type 2 Boehringer Ingelheim March 4 2020 --
NCT02953093 Completed Drug: Acarbose|Other: Placebo Aging Montefiore Medical Center August 30 2017 Phase 2
NCT02589353 Recruiting Drug: Acarbose Healthy Volunteers Oregon State University April 21 2017 Phase 4
NCT02527239 Unknown status Other: Prospective observational study Pompe''s Disease Royal Brompton & Harefield NHS Foundation Trust|Genzyme a Sanofi Company September 2015 --
NCT01961388 Withdrawn Drug: Bay G5421 Glucobay|Drug: Metformin Diabetes Mellitus Bayer August 2015 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Acarbose | Acarbose supplier | purchase Acarbose | Acarbose cost | Acarbose manufacturer | order Acarbose | Acarbose distributor